Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin
BackgroundEltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT).MethodsForty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1340908/full |
| _version_ | 1797219306155540480 |
|---|---|
| author | Yahan Li Fansheng Kong Guanchen Bai Yujie Jiang Wenlu Zhang Xue Sun Xiaohui Sui Ying Li Mei Ding Dai Yuan Xin Wang Xin Wang Xin Wang Xin Wang Xiaosheng Fang |
| author_facet | Yahan Li Fansheng Kong Guanchen Bai Yujie Jiang Wenlu Zhang Xue Sun Xiaohui Sui Ying Li Mei Ding Dai Yuan Xin Wang Xin Wang Xin Wang Xin Wang Xiaosheng Fang |
| author_sort | Yahan Li |
| collection | DOAJ |
| description | BackgroundEltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT).MethodsForty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >50 × 109/L or 1 month after HSCT. Fifty-one patients in the same period received thrombopoietin (TPO) to promote PLT graft after HSCT and served as a control group.ResultsA total of 51 patients who applied TPO during the same period were treated as a control. In the eltrombopag group, the median time to white blood cells (WBC) graft was 12 days (range, 10-17 days) and the PLT graft was 15 days (range, 10-30 days), whereas for the patients in the TPO group, the median time to WBC and PLT graft was 12 days (range, 9-23 days) and 15.5 days (range, 9-41 days), respectively. In the first month after HSCT, the median WBC count in the eltrombopag group was 4.41 × 109/L (range, 0.87-40.01 × 109/L) and the median PLT was 89x109/L (range, 30-401 × 109/L); the median WBC and PLT \counts in the TPO group were 4.65 × 109/L (range, 0.99-23.63 × 109/L) and 86 × 109/L (range, 5-512 × 109/L), respectively. Patients in the TPO or eltrombopag group did not experience serious side effects after drug administration, and the difference in side effects on liver and kidney function between the two groups was not statistically significant.ConclusionEltrombopag is safe and similarly promotes platelet engraftment to thrombopoietin after allogeneic HSCT. |
| first_indexed | 2024-04-24T12:31:33Z |
| format | Article |
| id | doaj.art-3a2168ffc4a646e6806b340ab5f769f4 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T12:31:33Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-3a2168ffc4a646e6806b340ab5f769f42024-04-08T04:27:04ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-04-011510.3389/fimmu.2024.13409081340908Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietinYahan Li0Fansheng Kong1Guanchen Bai2Yujie Jiang3Wenlu Zhang4Xue Sun5Xiaohui Sui6Ying Li7Mei Ding8Dai Yuan9Xin Wang10Xin Wang11Xin Wang12Xin Wang13Xiaosheng Fang14Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, The Affiliated Hospital of Shandong University of Traditional Chinese Medical, Jinan, Shandong, ChinaDepartment of Hematology, The Affiliated Taian City Centeral Hospital of Qingdao University, Taian, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, ChinaBranch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, ChinaNational Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, ChinaBackgroundEltrombopag has demonstrated efficacy in treating low platelet (PLT) levels, but it remains unclear whether eltrombopag can promote PLT engraftment after hematopoietic stem cell transplantation (HSCT).MethodsForty-one HSCT patients received eltrombopag 50 mg/d from +1 day until PLT >50 × 109/L or 1 month after HSCT. Fifty-one patients in the same period received thrombopoietin (TPO) to promote PLT graft after HSCT and served as a control group.ResultsA total of 51 patients who applied TPO during the same period were treated as a control. In the eltrombopag group, the median time to white blood cells (WBC) graft was 12 days (range, 10-17 days) and the PLT graft was 15 days (range, 10-30 days), whereas for the patients in the TPO group, the median time to WBC and PLT graft was 12 days (range, 9-23 days) and 15.5 days (range, 9-41 days), respectively. In the first month after HSCT, the median WBC count in the eltrombopag group was 4.41 × 109/L (range, 0.87-40.01 × 109/L) and the median PLT was 89x109/L (range, 30-401 × 109/L); the median WBC and PLT \counts in the TPO group were 4.65 × 109/L (range, 0.99-23.63 × 109/L) and 86 × 109/L (range, 5-512 × 109/L), respectively. Patients in the TPO or eltrombopag group did not experience serious side effects after drug administration, and the difference in side effects on liver and kidney function between the two groups was not statistically significant.ConclusionEltrombopag is safe and similarly promotes platelet engraftment to thrombopoietin after allogeneic HSCT.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1340908/fulleltrombopagthrombopoietinsafetyprognosisallogeneic hematopoietic stem cell transplantationplatelet engraftment |
| spellingShingle | Yahan Li Fansheng Kong Guanchen Bai Yujie Jiang Wenlu Zhang Xue Sun Xiaohui Sui Ying Li Mei Ding Dai Yuan Xin Wang Xin Wang Xin Wang Xin Wang Xiaosheng Fang Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin Frontiers in Immunology eltrombopag thrombopoietin safety prognosis allogeneic hematopoietic stem cell transplantation platelet engraftment |
| title | Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin |
| title_full | Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin |
| title_fullStr | Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin |
| title_full_unstemmed | Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin |
| title_short | Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin |
| title_sort | eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin |
| topic | eltrombopag thrombopoietin safety prognosis allogeneic hematopoietic stem cell transplantation platelet engraftment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1340908/full |
| work_keys_str_mv | AT yahanli eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT fanshengkong eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT guanchenbai eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT yujiejiang eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT wenluzhang eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT xuesun eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT xiaohuisui eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT yingli eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT meiding eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT daiyuan eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT xinwang eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT xinwang eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT xinwang eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT xinwang eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin AT xiaoshengfang eltrombopagcanpromoteplateletimplantationafterallogeneichematopoieticstemcelltransplantationassafelyandsimilarlytothrombopoietin |